{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-057804","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-08-18T23:56:38+00:00","discovered_at":"2026-08-19T10:05:00.682607+00:00","generated_at":"2026-08-19T10:05:32.817895+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity","bullets":["Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.","Company has until Oct 2, 2026 to submit a compliance plan; Nasdaq may grant extension to Feb 14, 2027.","Common stock continues trading on Nasdaq under 'SKYE'; no immediate effect on listing.","Company evaluating alternatives to regain compliance; no assurance of success.","Also disclosed proposed acquisition of Redx Pharma Limited (Transaction Agreement dated Aug 14, 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-057804","json":"https://secwatch.observer/filing/0001628280-26-057804.json","markdown":"https://secwatch.observer/filing/0001628280-26-057804.md","text":"https://secwatch.observer/filing/0001628280-26-057804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/0001628280-26-057804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-19T10:05:32.817895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}